These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 12676074

  • 1. Effects of valsartan with or without benazepril on blood pressure, angiotensin II, and endoxin in patients with essential hypertension.
    Ke YS, Tao YY, Yang H, Yu GH.
    Acta Pharmacol Sin; 2003 Apr; 24(4):337-41. PubMed ID: 12676074
    [Abstract] [Full Text] [Related]

  • 2. Effect of combination of valsartan with benazepril on blood pressure and left ventricular hypertrophy in SHR.
    Ke YS, Cao H, Yang T.
    Acta Pharmacol Sin; 2000 Nov; 21(11):1043-7. PubMed ID: 11501062
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM, Malacco E, Khder Y, Kandra A, Bönner G, Heintz D.
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
    Palatini P, Dorigatti F, Mugellini A, Spagnuolo V, Varì N, Ferrara R, Bertocchi F.
    Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006
    [Abstract] [Full Text] [Related]

  • 10. Effectiveness of valsartan for treatment of hypertension: patient profiling and hierarchical modeling of determinants and outcomes (the PREVIEW study).
    Van der Niepen P, Woestenburg A, Brié H, Vancayzeele S, MacDonald K, Denhaerynck K, Lee C, Hermans C, Abraham I.
    Ann Pharmacother; 2009 May; 43(5):849-61. PubMed ID: 19351876
    [Abstract] [Full Text] [Related]

  • 11. Angiotensin II receptor blockade with valsartan decreases plasma osteopontin levels in patients with essential hypertension.
    Kurata M, Okura T, Irita J, Enomoto D, Nagao T, Jotoku M, Miyoshi K, Desilva VR, Higaki J.
    J Hum Hypertens; 2011 May; 25(5):334-9. PubMed ID: 20664555
    [Abstract] [Full Text] [Related]

  • 12. Selective angiotensin receptor antagonism with valsartan decreases arterial stiffness independently of blood pressure lowering in hypertensive patients.
    Nakamura T, Fujii S, Hoshino J, Saito Y, Mizuno H, Saito Y, Kurabayashi M.
    Hypertens Res; 2005 Dec; 28(12):937-43. PubMed ID: 16671331
    [Abstract] [Full Text] [Related]

  • 13. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
    Pool JL, Schmieder RE, Azizi M, Aldigier JC, Januszewicz A, Zidek W, Chiang Y, Satlin A.
    Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
    [Abstract] [Full Text] [Related]

  • 14. Differential time effect profiles of amlodipine, as compared to valsartan, revealed by ambulatory blood pressure monitoring, self blood pressure measurements and dose omission protocol.
    Radauceanu A, Boivin JM, Bernaud C, Fay R, Zannad F, CIC General Practitioners Investigators' Group.
    Fundam Clin Pharmacol; 2004 Aug; 18(4):483-91. PubMed ID: 15312156
    [Abstract] [Full Text] [Related]

  • 15. Additional antihypertensive effect of drugs in hypertensive subjects uncontrolled on diltiazem monotherapy: a randomized controlled trial using office and home blood pressure monitoring.
    Karotsis AK, Symeonidis A, Mastorantonakis SE, Stergiou GS, Home-Di-Plus Study Group.
    Clin Exp Hypertens; 2006 Oct; 28(7):655-62. PubMed ID: 17060064
    [Abstract] [Full Text] [Related]

  • 16. Effects of the angiotensin II type 1 receptor antagonist valsartan on the expression of superoxide dismutase in hypertensive patients.
    Yang HY, Kao PF, Chen TH, Tomlinson B, Ko WC, Chan P.
    J Clin Pharmacol; 2007 Mar; 47(3):397-403. PubMed ID: 17322151
    [Abstract] [Full Text] [Related]

  • 17. Impact of supportive measures on drug adherence in patients with essential hypertension treated with valsartan: the randomized, open-label, parallel group study VALIDATE.
    Düsing R, Handrock R, Klebs S, Tousset E, Vrijens B.
    J Hypertens; 2009 Apr; 27(4):894-901. PubMed ID: 19300114
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study.
    Andrés A, Morales E, Morales JM, Bosch I, Campo C, Ruilope LM, Valsartan in Renal Transplantation Group.
    Transplant Proc; 2006 Oct; 38(8):2419-23. PubMed ID: 17097955
    [Abstract] [Full Text] [Related]

  • 19. A comparison of valsartan and perindopril in the treatment of essential hypertension in the malaysian population.
    Bavanandan S, Morad Z, Ismail O, Chandran A, Thayaparan T, Singaraveloo M.
    Med J Malaysia; 2005 Jun; 60(2):158-62. PubMed ID: 16114156
    [Abstract] [Full Text] [Related]

  • 20. Valsartan reduces interleukin-1beta secretion by peripheral blood mononuclear cells in patients with essential hypertension.
    Li QZ, Deng Q, Li JQ, Yi GH, Zhao SP.
    Clin Chim Acta; 2005 May; 355(1-2):131-6. PubMed ID: 15820487
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.